IP Library Granted Patent US 8,546,530
Granted Patent B2
US 8,546,530 · App. 12/743,323 · Granted Oct 1, 2013

Process for the manufacture of persilylated peptides

Inventors: Roland Callens (Grimbergen, BE); Thierry Delplanche (Mont-St-Guibert, BE)
Assignee: Solvay (Societe Anonyme)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,546,530
App. No.
12/743,323
Granted
Oct 1, 2013
Kind
B2
Abstract

Process for the manufacture of a peptide or peptide analog, which comprises (a) producing a persilylated peptide or persilylated peptide analogue by silylating a corresponding peptide by reaction with a silylating agent other than trimethylsilylcyanide, and (b) reacting a compound of formula (I) X-A-COOH wherein X is an amino protecting group, A is an amino acid, peptide or peptide analogue residue, and —COOH designates an optionally activated carboxylic group, with a persilylated peptide or a persilylated peptide analogue containing from 4 to 15 amino acids.

Claims (12)

1. A process for the manufacture of a peptide or peptide analogue, which comprises (a) producing a persilylated peptide or persilylated peptide analogue containing from 4 to 15 amino acids by silylating a corresponding peptide by reaction with a silylating agent other than trimethylsilylcyanide; and (b) reacting a compound of formula (I) X-A-COOH, wherein X is an amino protecting group, A is an amino acid, peptide or peptide analogue residue, and —COOH designates an optionally activated carboxylic group, with the persilylated peptide or persilylated peptide analogue of step (a).

2. The process according to claim 1 , wherein the persilylated peptide contains 4, 5, 6, 7, or 8 amino acids.

3. The process according to claim 1 , wherein the reaction of step (a) is carried out in an organic solvent.

4. The process according to claim 1 , wherein the silylating agent is N-methyl-N-trimethylsilylacetamide (MSA).

5. The process according to claim 3 wherein the organic solvent is N,N-dimethylacetamide (DMAC).

6. The process according to claim 1 , wherein 0.7 to 1.5 equivalents of silylating agent are used relative to the molar amount of functional groups to be silylated.

7. The process according to claim 1 , wherein A comprises 2, 3, 4, 5, 6, 7, 8 or 9 amino acids.

8. The process according to claim 1 , wherein X is an electron-withdrawing amino protecting group.

9. The process according to claim 8 , wherein X is a t-butoxycarbonyl group.

10. The process according to claim 1 , wherein the reaction of step (b) is carried out in the presence of a carboxyl group activating agent selected from the group consisting of pivaloyl chloride and isobutyl chloroformate.

11. The process according to claim 1 further comprising removing the group X from the compound produced by the reaction.

12. The process according to claim 4 , wherein the reaction of step (a) is carried out in an organic solvent which is N,N-dimethylacetamide (DMAC).

Assignments (2)
CHANGE OF NAME Recorded Jan 23, 2017
From: PEPTISYNTHA
To: CORDEN PHARMA BRUSSELS PC
Reel/Frame 041051/0152 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2013
From: SOLVAY
To: PEPTISYNTHA
Reel/Frame 031450/0742 →
Priority Claims (1)
EP 07121041 · Nov 19, 2007 · regional
Continuity (2)
Provisional Application 61014923 · Dec 19, 2007
Related Publication 20100298537A1 · Nov 25, 2010